Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Kioxia Holdings | Coca-Cola | Moderna | |
|---|---|---|---|
| Moat rating | narrow Kioxia's FY2025 Annual Securities Report (dated 2026-06-24) describes a real but bounded position. It records 'the limited number of major competitors in the flash memory business', and says its three manufacturing joint ventures with Sandisk let it 'make investments on a larger scale than if it were to invest alone and enjoy economies of scale in terms of capital expenditures and production efficiency'. Against that, the same Risk Factors section describes 'heavy global competition as advanced technologies are necessary for business execution', says 'in the flash memory market the Group's ability to decide prices is limited', that 'Some competitors possess technologies that the Group does not have, such as DRAM' and 'have greater financial strength than the Group', and records that the Group cut production from October 2022 to March 2024. Scale in a small field, not a barrier that protects Kioxia's returns through the cycle. | wide The FY2025 10-K's own competitive-strengths list leads with "leading brands with high levels of consumer recognition and loyalty" and "a worldwide network of bottlers and distributors of Company products", and the trademarks behind those brands are "valid as long as they are in use and/or their registrations are properly maintained" — an IP right the filing gives no expiry. Gross margin rose 59.5% to 61.1% to 61.6% across FY2023-FY2025 on the XBRL in the same annual filings, in an industry the filing itself calls "highly competitive". | narrow The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion. |
| Moat type | cost scale The advantage the company itself names is scale and capital efficiency. The Annual Securities Report says the Sandisk joint ventures, which procure the production equipment installed at Kioxia's Yokkaichi and Kitakami plants and 'sell 50% of their products to the Group and 50% to the Sandisk Group', let it 'enjoy economies of scale in terms of capital expenditures and production efficiency'. At its 2026 Investor Day (2026-06-02) management said that 'by leveraging our world-leading economies of scale, we have maintained a lower cost per gigabyte than the industry average', on a slide that cites the TechInsights NAND Market Report Q2 2026 as its source. The filing describes its technology work (layer stacking for BiCS FLASH, the move to QLC) and names 'a decline in competitiveness in production efficiency per gigabyte' as a risk if it falls behind. It does not present that technology as protected IP that rivals cannot match. | intangibles ip The filing locates the durable assets in intellectual property rather than scale: "our sparkling beverage and other beverage formulas are among the important trade secrets of our Company", and "We also own numerous trademarks that are very important to our business", which are "valid as long as they are in use and/or their registrations are properly maintained" — unlike a patent, no fixed term. | intangibles ip The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power." |
| Leadership | at parity TrendForce's 2Q26 NAND Flash ranking (2026-08-18) puts Kioxia fourth with revenue of about $10.72 billion. Its 13.6% share 'edged down', and it sits behind Samsung (29.3%), SK hynix Group and Micron, which moved up to third. TrendForce's 2Q26 enterprise SSD ranking (2026-09-01) also places it fourth, at $4.64 billion. On technology it is keeping pace: it began sampling the 332-layer 10th-generation BiCS FLASH on 2026-07-03, per its press release. The Annual Securities Report concedes that some competitors 'possess technologies that the Group does not have, such as DRAM' and 'have greater financial strength than the Group'. Kioxia is in the middle of a small group of peers. | co leader The filing claims leading BRANDS but never category leadership, and names "PepsiCo, Inc." as "a primary competitor" in many countries, alongside Nestle S.A., Keurig Dr Pepper Inc., Danone S.A., Suntory Beverage & Food Limited, Anheuser-Busch InBev, Kirin Holdings, Heineken N.V., Diageo plc and Red Bull GmbH. | co leader The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date." |
| Pricing power | weak The Annual Securities Report states that 'in the flash memory market the Group's ability to decide prices is limited, and in the medium- to long-term selling prices on a bit basis may decline at a similar pace as in the past'. Current margins follow the market. The first-quarter FY2026 results attribute the revenue jump primarily to 'a significant increase in average selling prices (ASPs) resulting from strong demand from data center customers focusing on generative AI'. Gross profit was ¥1,380,066 million on revenue of ¥1,767,117 million, against ¥71,179 million on ¥342,799 million a year earlier. In the 2026 Investor Day Q&A management said it believes 'market pricing will continue to reflect those supply-demand conditions'. | strong Three consecutive years of gross-margin expansion — 59.5% (FY2023), 61.1% (FY2024), 61.6% (FY2025) — through an inflationary period. The filing discloses the countervailing force itself: competitive pressures "may restrict our and our bottlers' ability to increase prices". | weak Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries." |
| Summary | Kioxia calls itself 'a specialized flash memory manufacturer'. It makes BiCS FLASH 3D NAND at Yokkaichi and Kitakami in Japan through three manufacturing joint ventures with Sandisk, whose output is sold 50% to Kioxia and 50% to Sandisk. FY2025 (year to March 2026) revenue was ¥2,337.6bn: SSD & Storage ¥1,362.6bn, Smart Devices ¥760.0bn and Other ¥215.0bn, with the Apple group alone at 20.4% of sales. Its moat is scale in a concentrated industry. TrendForce ranks it fourth in 2Q26 NAND revenue with a 13.6% share, and in August 2026 the partners announced anticipated investments in Japan of over $31 billion through 2032, contingent on government support. The same filing sets out the limits: limited ability to set prices; rivals that also make DRAM and have more financial strength; China's government-supported push for domestic semiconductor production; and a joint-venture agreement effective until 2034, with no decision yet on whether it continues after that. First-quarter FY2026 gross profit was ¥1,380,066 million on revenue of ¥1,767,117 million, against ¥71,179 million on ¥342,799 million a year earlier. The company attributes the jump primarily to a significant increase in average selling prices. | The asset is the trademarks and the secret formulas behind them; the bottling network is how they reach a shelf. The 10-K's own strengths list names both. What caps the moat sits on the same page: the competitive challenges include "a concentrated retail sector with powerful buyers able to freely choose among Company products, products of competitive beverage suppliers and individual retailers' own store or private-label beverage brands". | Moderna's 10-K rests its competitive case on the mRNA platform and the IP wrapped around it: the company states it believes its capabilities "across mRNA technology, drug discovery, development and manufacturing" differentiate it, and reports more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed abroad, 485 pending applications, and granted patents on Spikevax, mNEXSPIKE and mRESVIA projected to expire in 2041 (U.S.) and 2036 (Europe), plus trade secrets and manufacturing know-how it calls substantial. The filing is equally direct about the limits: the principal COVID rival's vaccine "is also based on mRNA technology"; a competitor's European Commission contract keeps Moderna out of many European COVID markets until year-end 2026; RSV sales are "minimal to date" behind Pfizer and GSK; and the risk factors warn that "the mRNA medicines field is growing rapidly, with increased competitive pressure from large and more established pharmaceutical companies." What is durable is science and plant rather than commercial position: Moderna bought and operates the Norwood (MTC) campus, completed a Marlborough site purpose-built for intismeran autogene that began shipping patient batches in September 2025, and runs UK, Canada and Australia facilities that were fully licensed in 2025, each government having entered a multi-year commitment to purchase mRNA products from the company. |
| Chain position | Upstream NAND flash and SSD supplier. The filing says much of its revenue 'depends on a limited number of customers and industries, such as major smartphone manufacturers and large IT companies, including hyperscalers that require SSDs'. The Apple group was 20.4% of FY2025 sales. | Outside this graph's supply chain: an AI-adopting incumbent whose beverage business buys AI as a tool rather than supplying it. | A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | -0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.35 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.05 at weight 0.20 · swarm bearish Editorial prior, not backtested. |